Abstract
Intracerebral haemorrhage is an important public health problem leading to high rates of death and disability in adults. Although the number of hospital admissions for intracerebral haemorrhage has increased worldwide in the past 10 years, mortality has not fallen. Results of clinical trials and observational studies suggest that coordinated primary and specialty care is associated with lower mortality than is typical community practice. Development of treatment goals for critical care, and new sequences of care and specialty practice can improve outcome after intracerebral haemorrhage. Specific treatment approaches include early diagnosis and haemostasis, aggressive management of blood pressure, open surgical and minimally invasive surgical techniques to remove clot, techniques to remove intraventricular blood, and management of intracranial pressure. These approaches improve clinical management of patients with intracerebral haemorrhage and promise to reduce mortality and increase functional survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1632-1644 |
| Number of pages | 13 |
| Journal | The Lancet |
| Volume | 373 |
| Issue number | 9675 |
| DOIs | |
| State | Published - 2009 |
Bibliographical note
Funding Information:AIQ has received funding from National Institutes of Health RO-1-NS44976-01A2 (medication provided by ESP Pharma), American Heart Association Established Investigator Award 0840053N, and Minnesota Medical Foundation (Minneapolis, MN, USA). ADM is the director of the Newcastle Neurosurgery Foundation, and has received honoraria for attending Advisory Committee Meetings for Codman and for Novo Nordisk. DFH receives funding through the US Food and Drug Administration orphan-drugs programme grant 5RO1-FD 001693, National Institute of Neurological Disorders and Stroke (NINDS) planning grant, 1R34-NS056638, MISITIE: NINDS, 1R01-NS 046309, Jeffrey and Harriet Legum professorship, Genentech, sponsored research agreement; he also has disavowed interest in this patent (Johns Hopkins University use patent application # 10/509,694) and has received an honorarium from Novo Nordisk.